Endpoints News

Teva's second chance		Read in browser

Thank you for reading, dupa dupackia!

basic

UPGRADE

M T Wed Th F

19 August, 2026

Twenty new honorees join the 140-plus women Endpoints News has recognized for reshaping biopharma. How did they get there, and what's changed? Join us for exclusive interviews, in-depth profiles and a frank look at gender representation in the industry today. Register now.

news

Merck, Moderna declare Phase 3 success for personalized mRNA cancer vaccine

Exclusive: Third death in China's popular but opaque trials revealed, this time in CAR-T

Federal appeals court revives part of Teva's IRA case as Austedo price cuts loom

Trump to pick Heidi Overton to lead the FDA following a run of volatile leadership

Aug 19

1:00 pm ET

From pilots to production: AI across R&D, safety, regulatory, and clinical

in case you missed it

Amylyx declares late-stage win with a GLP-1 antagonist in its post-ALS reset

Trump is taking credit for lower list prices. But a Biden-era law did a lot of the heavy lifting

CSL calls Tavneos withdrawal in Europe a 'significant headwind' for sales

BioMarin does another small deal to get early-stage bone disease asset

Leo Pharma to license Tanabe’s rare disease drug for pain with sun exposure

More Alzheimer's research trouble

DEREK LOWE, IN THE PIPELINE

Novo starts testing low-dose Wegovy pills in new obesity study

In case you missed it, Ryan Cross has a gripping story on a patient death from an investigator-initiated study in China. If you have any leads or tips, you can reach him here or on Signal at RyanCross.25.

Reynald Castaneda

Deputy Editor, Endpoints News

2029 Becker Drive; Lawrence, Kansas 66047 USA Privacy and deletion: help@endpointsnews.com

Endpoints Studio
Endpoints Webinars